氯胺酮对焦虑的影响:来自成人抑郁氯胺酮研究的结果
本研究为多中心4周随机双盲活性对照(咪达唑仑)试验的二次分析,纳入至少接受一次治疗的174例难治性重性抑郁障碍患者。队列1固定低剂量氯胺酮(0.5 mg/kg)的HAM-A减分无统计学意义,队列2灵活剂量(0.5-0.9 mg/kg)减分显著优于咪达唑仑,但疗效在治疗结束4周后未维持。
要点
- 队列2灵活剂量皮下氯胺酮使HAM-A评分显著降低,优于咪达唑仑。
- 队列1固定低剂量氯胺酮的HAM-A减分无统计学意义。
- 焦虑改善由MADRS总分中介,且治疗结束4周后未维持。
核心结论
- 皮下给予足量氯胺酮可减轻难治性重性抑郁障碍患者的焦虑。
研究设计与样本
- 成人抑郁氯胺酮研究为多中心4周随机双盲活性对照(咪达唑仑)试验的二次分析。
- 队列1采用固定低剂量氯胺酮(0.5 mg/kg),队列2经方案修订后采用灵活反应引导剂量(0.5-0.9 mg/kg)。
- 分析纳入至少接受一次治疗的全部174例参与者,采用混合效应重复测量模型评估主要焦虑指标。
主要发现
- 队列1(n=68)HAM-A评分减分为-1.4(95% CI [-8.6, 3.2],P=0.37),无统计学意义。
- 队列2(n=106)HAM-A评分减分为-4.0(95% CI [-10.6, -1.9],P=0.0058),优于咪达唑仑。
- 上述效应由MADRS总分中介,且在治疗结束4周后未维持。
- MADRS第3项(内心紧张)在队列2显著降低(P=0.026),队列1未显著降低(P=0.96)。
关键数值与推荐
- 主要焦虑指标为汉密尔顿焦虑量表(HAM-A),次要指标为MADRS第3项内心紧张。
- 评估时间点为基线、4周(治疗结束)及治疗结束4周后。
- 试验注册号:ACTRN12616001096448。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anxiety disorders and treatment-resistant major depressive disorder (TRD) are often comorbid. Studies suggest ketamine has anxiolytic and antidepressant properties. AIMS: To investigate if subcutaneous racemic ketamine, delivered twice weekly for 4 weeks, reduces anxiety in people with TRD. METHOD: The Ketamine for Adult Depression Study was a multisite 4-week randomised, double-blind, active (midazolam)-controlled trial. The study initially used fixed low dose ketamine (0.5 mg/kg, cohort 1), before protocol revision to flexible, response-guided dosing (0.5-0.9 mg/kg, cohort 2). This secondary analysis assessed anxiety using the Hamilton Anxiety (HAM-A) scale (primary measure) and 'inner tension' item 3 of the Montgomery-Åsberg Depression Rating Scale (MADRS), at baseline, 4 weeks (end treatment) and 4 weeks after treatment end. Analyses of change in anxiety between ketamine and midazolam groups included all participants who received at least one treatment (n = 174), with a mixed effects repeated measures model used to assess the primary anxiety measure. The trial was registered at www.anzctr.org.au (ACTRN12616001096448). RESULTS: In cohort 1 (n = 68) the reduction in HAM-A score was not statistically significant: -1.4 (95% CI [-8.6, 3.2], P = 0.37), whereas a significant reduction was seen for cohort 2 (n = 106) of -4.0 (95% CI [-10.6, -1.9], P = 0.0058), favouring ketamine over midazolam. These effects were mediated by total MADRS and were not maintained at 4 weeks after treatment end. MADRS item 3 was also significantly reduced in cohort 2 (P = 0.026) but not cohort 1 (P = 0.96). CONCLUSION: Ketamine reduces anxiety in people with TRD when administered subcutaneously in adequate doses.
引用
- Mills NT, Nikolin S, Glozier N, et al. Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study. Br J Psychiatry. 2025. PMID: 39763417. doi:10.1192/bjp.2024.250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。